Stifel raises Hinge Health stock price target to $66 from $63, cites strong growth

Hinge Health Inc. (NYSE:HNGE) saw Stifel raise its price target to $66 while maintaining a Buy rating, driven by strong business momentum, conservative consensus estimates, and the company's clear market leadership in asynchronous musculoskeletal care. This upgrade follows Hinge Health's impressive Q2 results, which led to a significant increase in 2025 guidance, and robust Q1 revenue growth of 55% year-over-year. The positive analyst sentiment, also reflected in raised targets from Piper Sandler and Citizens JMP, underscores the investment community's growing confidence in the healthcare technology firm's strategic positioning and growth trajectory.

Analysis

Hinge Health Inc. (HNGE) is exhibiting significant positive momentum, underscored by a series of analyst upgrades and strong fundamental performance. Stifel raised its price target to $66, maintaining a Buy rating, citing expectations for robust new client additions and retention in the current selling season. This optimism is supported by a proprietary benefit manager survey identifying Hinge as the clear leader in the under-penetrated asynchronous musculoskeletal care market. Stifel's analysis suggests consensus revenue growth estimates of 20% for 2026 and 16% for 2027 are conservative, positing that growth is more likely to reach the mid-20% range with above-consensus margins. This bullish outlook follows the company's recent performance, including a 55% year-over-year revenue increase in its first reported quarter to $139.1 million, which surpassed consensus, and a significant raise in its 2025 revenue and EBIT guidance. The broader investment community has responded favorably, with Piper Sandler and Citizens JMP also increasing their price targets to $70 and $65, respectively. However, Baird's initiation with a Neutral rating and a $56 target suggests a more cautious view, even while acknowledging the company's compelling product, which includes its proprietary AI-powered technology and an FDA-cleared device.

Key Decisions for Investors

• Given the strong momentum, raised corporate guidance, and multiple analyst upgrades suggesting consensus estimates are conservative, investors could consider initiating or increasing positions in HNGE to gain exposure to its leadership in a high-growth healthcare sub-sector.
• Investors should weigh the company's growth prospects against its valuation, which Stifel notes is approximately 7.5 times 2026 revenue and 38 times free cash flow, to determine if the premium is justified by the projected mid-20% growth trajectory.
• Monitor upcoming company reports on new client additions and retention following the seasonally strong selling period ending in October, as these will be critical data points for validating the optimistic growth thesis.
• While analyst sentiment is broadly positive, the Neutral rating from Baird warrants consideration; investors should continue to assess the competitive landscape and Hinge Health's ability to maintain its market-leading position and margin profile.